ProQR Therapeutics
PRQR
27 hedge funds and large institutions have $37.1M invested in ProQR Therapeutics in 2017 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 6 closing their positions.
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
17% more funds holding
Funds holding: 23 → 27 (+4)
4.07% less ownership
Funds ownership: 40.2% → 36.12% (-4.1%)
24% less capital invested
Capital invested by funds: $48.9M → $37.1M (-$11.8M)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.59M |
| 2 |
AG
Artal Group
Luxembourg
|
+$1.44M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.25M |
| 4 |
OPPM
Opus Point Partners Management
New York
|
+$1.1M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$829K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$3.56M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$690K |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$160K |
| 4 |
PCM
Prelude Capital Management
New York
|
-$71K |
| 5 |
VF
Virtu Financial
New York
|
-$64K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| $3K | – | – | – |
|
|
27
Janus Henderson Group
London,
United Kingdom
| – | -$690K | -142,350 | Closed |
|
|
PCM
28
Prelude Capital Management
New York
| – | -$71K | -14,700 | Closed |
|
|
VF
29
Virtu Financial
New York
| – | -$64K | -13,150 | Closed |
|
30
Geode Capital Management
Boston,
Massachusetts
| – | -$59K | -12,211 | Closed |
|
31
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$46K | -9,500 | Closed |
|
|
TDC
32
Thompson Davis & Co
Richmond,
Virginia
| – | -$10K | -2,000 | Closed |
|
PRQR Hedge Fund Activity: Q4 2017 in Review
27 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q4 2017, worth a combined $37.1M — down 24% from $48.9M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new PRQR positions and 6 closed out — a net gain of 5 holders — while 4 added to existing stakes and 6 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $3.59M. The largest seller was OrbiMed, cutting an estimated $3.56M.
- 27 institutional investors held ProQR Therapeutics (PRQR) as of Q4 2017, up from 23 in Q3 2017.
- Funds reported $37.1M of ProQR Therapeutics stock for Q4 2017, down 24% quarter-over-quarter.
- 11 funds opened new ProQR Therapeutics positions in Q4 2017 and 6 closed out, a net change of +5 holders.
- The largest ProQR Therapeutics buyer in Q4 2017 was Adage Capital Partners, an estimated $3.59M added.
- The largest ProQR Therapeutics seller in Q4 2017 was OrbiMed, an estimated $3.56M sold.
Based on aggregated 13F filings for Q4 2017.